Re:Anti-Cancer Agent Stops Metastasis In Its Tracks
by freesciencenow on Tuesday April 20, 2010 @03:17PM
(#1280316)
Yes, regular. However, I hope this isn't gonna be a throw-away login: I've done this before with my regular account, and plan to do it every time I see a link posted where the paper is behind a paywall, both to help the discussion and as an act of civil disobedience. So I decided to create an account for this purpose.
Re:Anti-Cancer Agent Stops Metastasis In Its Tracks
by pingou on Tuesday April 20, 2010 @05:43AM
(#1279020)
It looks promising, but I saw so much articles on new miraculous treatments that I became a little bit more dubious every time I read an article like this one.
Re:Anti-Cancer Agent Stops Metastasis In Its Tracks
by ryanhuff on Monday April 19, 2010 @10:05PM
(#1278388)
Its interesting (to me) that some of the funding for this work was provided by the Department of Defense. Is this common for the DoD to fund this type of research?
Re:Anti-Cancer Agent Stops Metastasis In Its Tracks
by bedris on Tuesday April 20, 2010 @12:08AM
(#1278601)
The DoD also funds the National Defense Science and Engineering Graduate (NDSEG) Fellowship, which funds (among other areas) biomedical research being carried out by graduate students.
Re:Anti-Cancer Agent Stops Metastasis In Its Tracks
by carbocation on Monday April 19, 2010 @10:18PM
(#1278413)
You're right :( The article is pretty remarkable for its breadth. Let me try to give a synopsis:
They synthesize a new biotinylated ketone. They determine that this compound binds to fascin, which has some molecular biological background as something that bundles actin, and some population biological background as something that corresponds with worse survival in breast cancer. They then develop the crystal structure for fascin both with and without their new molecule, and they show that their macroketone binds to the actin binding sites on fascin. They also use electron microscopy to determine that their new molecule indeed appears to disrupt actin bundling by fascin.
They then gave to immune-deficient mice human breast cancer cells. These cells typically metastasize aggressively. They gave the mice a 'placebo' and/or shRNA against fascin and/or their new macroketone. The shRNA and their macroketone successfully cut the metastatic burden by ~50-80%. (shRNA ultimately leads to downregulation of the mRNA of target proteins, so their shRNA should reduce fascin synthesis while their macroketone reduces the function of already-made fascin.)
It's not a silver bullet against metastatic breast cancer, but it's an impressively complete story for one paper. And promising, perhaps, as a therapeutic.
Paywalls for scientific research are evil.
Do something people.
Here: http://209.20.67.195/misc/nature08978.pdf
[1] http://mitworld.mit.edu/video/534
So there is as much socialism in the US as in Sweden? :-)
This gave me a sense of wonder insight into how large the large countries are.
You can find more at grants.gov: http://www.grants.gov/search/agency.do
More about the fellowship: http://ndseg.asee.org/
They synthesize a new biotinylated ketone. They determine that this compound binds to fascin, which has some molecular biological background as something that bundles actin, and some population biological background as something that corresponds with worse survival in breast cancer. They then develop the crystal structure for fascin both with and without their new molecule, and they show that their macroketone binds to the actin binding sites on fascin. They also use electron microscopy to determine that their new molecule indeed appears to disrupt actin bundling by fascin.
They then gave to immune-deficient mice human breast cancer cells. These cells typically metastasize aggressively. They gave the mice a 'placebo' and/or shRNA against fascin and/or their new macroketone. The shRNA and their macroketone successfully cut the metastatic burden by ~50-80%. (shRNA ultimately leads to downregulation of the mRNA of target proteins, so their shRNA should reduce fascin synthesis while their macroketone reduces the function of already-made fascin.)
It's not a silver bullet against metastatic breast cancer, but it's an impressively complete story for one paper. And promising, perhaps, as a therapeutic.